You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEC said the deal will bolster its cancer immunotherapy development programs, which are focused on ovarian cancer and head and neck cancer.
Exact said it will pay $72 per share for Genomic Health for a total transaction price of $2.8 billion in cash and stock.
The groups will use Helomics' artificial intelligence-based platform to develop tools to provide predictive therapeutic recommendations for ovarian and thyroid cancers.
The firm is using automated laboratory testing, artificial intelligence, and single-cell omics for a "precision" approach to cancer drug discovery.
The firm is focused on developing oncology drugs that target mutations in the RAS pathway.
The partners are working together to advance tests that will identify which cancer patients have Notch activating mutations and fusions.
The firm said it needs more time to ensure that the DetermaVu assay is providing the most consistent and sensitive results for patients.
Among Kiromic's platforms is an artificial intelligence product that combines genomic sequencing, proteomic, and clinical data to provide predictive algorithms.
The deal covers the PlexBio IntelliPlex diagnostic instrument platform and reagent kits for oncology and infectious disease testing.
The LeukoStrat CDx FLT3 Mutation Assay can now be used in Japan as the CDx for quizartinib for the treatment of FLT3-ITD positive relapsed or refractory AML.
Resolution is developing its liquid biopsy assay as a companion diagnostic for niraparib in metastatic castration-resistant prostate cancer.
The Swedish company is developing sequencing- and PCR-based tests and services that quantify aberrations in DNA, RNA, and circulating tumor DNA.
The agreement is part of Biocartis' long term plans to expand its presence in the oncology field by building a menu of tests for immunotherapies.
Caris will use its whole-transcriptome sequencing assay and Molecular Intelligence Trials service to identify patients for a phase II clinical trial.
This new VC round brings the cancer informatics and precision medicine company's total fundraising to $520 million and its valuation to $3.1 billion.
The company is commercializing a method developed by researchers at Johns Hopkins that detects cancer with high specificity from a blood sample.
The companies will work together first to develop a companion diagnostic for Bayer's TRK inhibitor larotrectinib, with opportunities to expand to other drugs and drug candidates thereafter.
The group will define and quantify Stroma Liquid Biopsy biomarkers in Leiden University-collected sera to correlate them with Leiden's tumor-stroma ratio scoring methods.
MammaPrint classifies patients as either high risk or low risk of recurrence over a 10-year period while BluePrint classifies patients by breast cancer subtype.
FLX Bio will apply Personalis' ImmunoID Next platform as part of a Phase I/II clinical trial evaluating its FLX475 drug in cancer therapy.